Considering a number of treatment-related studies, HER4 seems to favorably or unfavorably predict a variety of BC therapies [19,20], including endocrine treatments (with, e.g., the anti-estrogen tamoxifen or related substances). This evidence concerns the gene ERBB4 and breast cancer.